“Committed to making the difference”
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 as a spin-out from Bayer's virology and bacteriology research department, AiCuris is now an established “powerhouse for anti-infectives” and is one of the few biotech companies world-wide to have successfully brought a drug to market, and therefore to patients (Prevymis® 2017/18).
Today AiCuris has an innovative pipeline of anti-infective agents and a team of internationally recognized scientists in Research and Development. By focusing on therapeutic areas with high medical need, the company is positioned for growth and success.
Corona diagnostic support for NRW
|Together with state-run veterinary institutes in NRW AiCuris is involved in carrying out approximately 20,000 tests against SARS-CoV-2|
• Following the increased incidence of coronavirus infections among employees of a slaughterhouse in Coesfeld, all of the approx. 20,000 employees and contract workers of slaughterhouses in NRW are currently being tested
• AiCuris has been involved at many levels since the outbreak of the pandemic and has established and made available SARS CoV-2 testing capacities at short notice to contribute to the fight against the corona pandemic
Early Access Program for Pritelivir
|AiCuris collaborates with myTommorrows to initiate an Early Access Program for Pritelivir|
You're a patient or a doctor interested in the program? Please find more information here.
AiCuris Provides Corporate Update
|AiCuris Anti-infective Cures GmbH today provided a strategic update, outlining its recent achievements and plans for future growth.|